Sabrina He is counsel in O'Melveny’s Beijing office. Sabrina’s practice focuses on capital markets transactions and securities law advisory work. She has represented issuers and investment banks in initial public offerings and subsequent financing involving a variety of industries. Sabrina also regularly advises public companies and shareholders on U.S. securities law compliance and stock exchange listing rules, as well as corporate governance matters.
In addition to her operating company representations, Sabrina has extensive experience with special purpose acquisition companies (SPACs) sponsored by private equity funds, broker-dealers and high-profile individuals in their initial public offerings and business combinations. Sabrina was one of the lead counsel for the US$1.18 billion de-SPAC deal between Blue Safari Group Acquisition Corp. and Bitdeer, and concurrent listing of the combined company on Nasdaq, which was recognized as “Deal of the Year” for 2023 by China Business Law Journal.
Prior to joining O’Melveny, Sabrina practiced at the New York and Beijing offices of leading international law firms and established middle-market firms.
Capital Markets
- IPOs and Concurrent Listings:
Benitec Biopharma (Nasdaq), Beneunder (HKEX), Bitdeer Technologies (Nasdaq), Carsgen Therapeutics (HKEX), Esco Lifesciences (HKEX), Fiscal Note (NYSE), Medirom Healthcare Technologies (Nasdaq), Mega Genomics (HKEX), MingZhu Logistics (Nasdaq), Perfect Corp. (NYSE), Skillful Craftsman Education (Nasdaq), and Wah Fu Education Group (Nasdaq)
- SPAC IPOs:
CF Acquisition Corp. IV to VIII (Nasdaq), CF Finance Acquisition Corp. I to III (Nasdaq), Chenghe Acquisition II Co. (NYSE), Far Point Acquisition Corp. (NYSE), Hennessy Capital Acquisition Corp. IV (Nasdaq), and Kayne Anderson Acquisition Corp. (Nasdaq)
- Follow-on offerings:
UP Fintech, Atossa Therapeutics, Castor Maritime, Cellular Biomedicine Group, Contrafect Corporation, Cytori Therapeutics, Genetic Technologies, Inspired Entertainment, Seanergy Maritime, Euroseas, and Top Ships
Mergers & Acquisitions
- Cellular Biomedicine Group in the strategic investment by Novartis AG and related collaboration with respect to production of CAR-T therapy Kymriah®
- Co-counsel to Primavera Capital in the $1.5 billion de-SPAC merger of Primavera Capital Acquisition Corp. with Lavine Group
- CF Finance Acquisition Corp. II in the US$1.6 billion de-SPAC merger with View, Inc. and concurrent listing of the combined company on Nasdaq
- Global Partner Acquisition Corp. in the US$550 million de-SPAC merger with Purple Innovation Inc. and concurrent listing of the combined company on Nasdaq
- JM Global Holding in the US$92 million de-SPAC transaction with China Sunlong Environmental Technology
- Tiberius Acquisition Corporation in the US$390 million de-SPAC merger with International General Insurance
- Holdings and concurrent listing of the combined company on Nasdaq
Compliance
- Advising U.S. public companies including Cellular Biomedicine Group, Inspired Entertainment, and Wah Fu Education on their securities law compliance matters
Including work performed prior to joining O’Melveny and ongoing proposed listing matters
Languages
- English
- Mandarin
Admissions
- District of Columbia
- New York
Education
- University of Illinois, J.D., with honors
- University of San Francisco, LL.M.
- Peking University, LL.B., with honors
- Peking University, B.S., Psychology